Soriano-Ursúa MA, Cordova-Chávez RI, Farfan-García ED, Kabalka G. Boron-containing compounds as labels, drugs, and theranostic agents for diabetes and its complications. World J Diabetes 2024; 15(6): 1060-1069 [PMID: 38983826 DOI: 10.4239/wjd.v15.i6.1060]
Corresponding Author of This Article
Marvin A Soriano-Ursúa, MD, PhD, Professor, Department of Physiology, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Ciudad de México 11340, Mexico. msoriano@ipn.mx
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Jun 15, 2024; 15(6): 1060-1069 Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1060
Boron-containing compounds as labels, drugs, and theranostic agents for diabetes and its complications
Marvin A Soriano-Ursúa, R Ivan Cordova-Chávez, Eunice D Farfan-García, George Kabalka
Marvin A Soriano-Ursúa, Department of Physiology, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico
R Ivan Cordova-Chávez, Department of Physiology, Instituto Politécnico Nacional, Mexico City 11340, Mexico
Eunice D Farfan-García, Department of Biochemistry, Instituto Politécnico Nacional, Mexico City 11340, Mexico
George Kabalka, Department of Chemistry, The University of Tennessee, Knoxville, TN 37996, United States
Author contributions: Soriano-Ursúa MA and Cordova-Chávez RI designed the overall concept and outline of the manuscript; Soriano-Ursúa MA, Farfán-García ED, and Kabalka G contributed to the discussion and design of the manuscript; and all authors contributed to the writing, and editing the manuscript, illustrations, chemistry discussion, and review of literature.
Supported bythe Secretaría de Investigación y Posgrado, No. M2143, No. M2303, No. 20232777, and No. 4288/2023.
Conflict-of-interest statement: All authors declare nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Marvin A Soriano-Ursúa, MD, PhD, Professor, Department of Physiology, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, Ciudad de México 11340, Mexico. msoriano@ipn.mx
Received: December 4, 2023 Peer-review started: December 4, 2023 First decision: February 18, 2024 Revised: February 25, 2024 Accepted: March 28, 2024 Article in press: March 28, 2024 Published online: June 15, 2024 Processing time: 190 Days and 14.6 Hours
Abstract
Diabetes is a disease with a high global burden. Current strategies have failed to limit the advancement and impact of the disease. Successful early diagnosis and treatment will require the development of new agents. In this sense, boron-containing compounds have been reported as agents with the ability to reduce glycemia and lipidemia. They have also been used for labeling and measuring carbohydrates and other molecules linked to the initial stages of diabetes and its progression. In addition, certain boron compounds bind to molecules related to diabetes development and their biological activity in the regulation of elevated glycemia. Finally, it should be noted that some boron compounds appear to exert beneficial effects on diabetes complications such as accelerating wound healing while ameliorating pain in diabetic patients.
Core Tip: Diabetes is a high-global burden malady. Boron-containing compounds, from diet or administered as drugs, are promising agents to prevent or reduce progression in diabetic patients. Emerging experimental data offer promise of potential applications in the diagnosis and treatment of diabetes and its complications.
